Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Na ïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan

ConclusionOur analysis suggests that VDZ is dominant or cost-effective compared with other branded biologics for the treatment of anti-TNF-na ïve patients with moderate-to-severe UC in Japan.
Source: PharmacoEconomics - Category: Health Management Source Type: research